THOUSAND OAKS, Calif., Oct. 7, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol ...
Amgen announced the presentation of efficacy and safety data from the CodeBreaK 100 phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received Lumakras (sotorasib). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results